Osteoporosis Drug Shows Promise -- Even in Men

Although the data do not rule out the possibility that osteonecrosis could occur with denosumab, it was encouraging to see no cases thus far, Cummings suggested. He said follow-up of FREEDOM participants would continue for 10 years, which may provide a more definitive view of the risk.

Denosumab's manufacturer, Amgen, has not yet announced the pricing for the drug. Nevertheless, as a biologic drug, denosumab is widely expected to be relatively expensive.

But another academic specialist contacted by MedPage Today and ABC News suggested a higher price could be acceptable given denosumab's potential advantages.

Endocrinologist Dr. Roberto Pacifici of Emory University in Atlanta said the "number needed to treat" in preventing fractures has been low in the denosumab studies reported to date.

The Question of Cost

"Therefore the cost of the drug is likely to be [worthwhile] in many patients," he said. "Guidelines will have to be developed in order to use this agent in the most cost-effective way."

Cummings said that if the drug is approved, he would consider it primarily for patients with a poor history on bisphosphonates.

"Those who have had trouble with oral drugs," because of side effects or compliance problems, would be the main candidates for denosumab, he said.

Another point in denosumab's favor, Cummings said, is that it is less persistent in bone than many bisphosphonates, making its activity potentially reversible — an important point for patients experiencing adverse effects.

In addition, Dr. Khosla pointed out, "since bisphosphonates are cleared by the kidney and contraindicated in patients with renal insufficiency, denosumab (which is cleared by nonrenal metabolism) may prove to be a safe drug in these patients, although studies that directly address this issue need to be done."

Amgen filed last December for FDA approval of the agent for treatment and prevention of postmenopausal osteoporosis in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer. The two trials were funded by Amgen.

This article was developed in collaboration with ABC News.

-- This embed didnt make it to copy for story id = 8302489. -- This embed didnt make it to copy for story id = 8302489. -- This embed didnt make it to copy for story id = 8302489.
Page
  • 1
  • |
  • 2
Join the Discussion
You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.
blog comments powered by Disqus
 
You Might Also Like...
See It, Share It
PHOTO: Makeup Artist Uses Chin as Canvas
Laura Jenkinson/Caters News Agency
PHOTO: Left, Texas Governor Rick Perry poses for his official portrait. Right, Perrys mug shot taken on August 19, 2014 after the Governor was indicted on two felony charges for an alleged abuse of power.
Texas State Governors Office | Travis County Sheriffs Office
PHOTO: Robin Williams and Billy Crystal walk the red carpet before a gala on August 4, 2012 in St. Paul, Minnesota.
Adam Bettcher/Getty Images for Starkey Hearing Foundation
PHOTO: Elise Mosca attends ABCs Bachelor In Paradise Premiere Party held at Mixology101 & Planet Dailies, Aug. 4, 2014, in Los Angeles.
Jesse Grant/Getty Images for Leisure Opport